| Abstract: | In the search for new therapeutic targets for depression and other stress-related disorders, much attention has focused on neurokinin-1 receptor (NK1r) antagonists. Progress toward NK2r and NK3r antagonists for the treatment of CNS disorders is also increasing, with multiple chemical series being reported. This review focuses on the patent literature since 2003, regarding these and related developments, for the medicinal chemistry of neurokinin antagonists as targets for depression and stress-related disorders. |
